FDA Reviews Asthma Medication Safety Data
The FDA is reviewing information to determine the safety of Xolair.
Press Release Service – Wired PR News – Information about the asthma medication Xolair, has recently been placed under review by the Food and Drug Administration (FDA). As reported by the Associated Press (AP), Xolair, which was placed on the market in 2003, may possibly be linked to serious health issues, according to preliminary data from a study on 5,000 patients who took the medication.
As noted in the report, taken through injection, the drug, created by Swiss pharmaceutical company Novartis, was initially approved by the FDA to treat people ages 12 and up who suffer from moderate to severe asthma that cannot be controlled by inhalants. Recent data proposes that Xolair can increase the chances of fatal conditions such as stroke or heart attack.
Tara Cooper, a spokesperson for Swiss drugmaker Genetech, is quoted by the AP as stating, “At this time there is insufficient information for the companies to change their assessment of the benefit-risk profile for Xolair.”
WiredPRNews.com – The latest in Health News.
Tags: asthma, Drug, Drugmaker, FDA, heart attack, medication, Novartis, pharmaceutical company, review, stroke, XolairOnline Health & Fitness News Press Release Distribution - WiredPRNews.com
- FREE Local Childhood Obesity Prevention Program Changes Kids Lives
- New Classification System for Air Filters Homes in on Efficiency, Savings
- Soprano Laser Hair Removal Now More Effective then IPL
- ‘New Year, New You’ Already in Jeopardy, As Brits Quit The Gym!
- Sustainability in the Workplace: Healthier Air, Higher Morale
- High Dose Rate Electronic Radiation Skin Cancer Treatment Now Available in US
- Chicago’s Gold Coast Goes Green As Skin Care Line Opens Flagship Sales Office
- Free Exercise Manual Aims to Reduce Childhood Obesity
- No Texting While Paddling: SUP Eco Adventures Provides THE Alternative
- Sandusky Accusers Get Foundation’s Help
